The Serum Institute of India (SII) on Saturday said it would apply for an emergency license to use Oxford’s Kovid-19 vaccine in the next two weeks. Serum Institute chief executive Adar Poonawalla said on Saturday that the vaccine and post-transplantation will be initially distributed in India and later in Africa.
Adar Poonawal’s statement came after Prime Minister Narendra Modi visited the serum. Responding to the question of the distribution of the ‘Coveshield vaccine’ in the country, Poonawala said that we are in the process of applying for an emergency permit within the next two weeks. So we have to wait and see it.
Poonavala said the vaccine will be initially distributed in India and then look at Kovacs countries, mainly in Africa. The United Kingdom and European markets are dominated by AstraZeneca and Oxford. If they need our help to increase their productivity, we are always there to support them.
Serum, the world’s largest vaccine manufacturer, has signed a vaccine-making contract developed by the Jenner Institute at Oxford University in collaboration with British-Swedish pharma company AstraZeneca. The University of Oxford and AstraZeneca said on Monday that their Kovid-19 vaccine is 90 percent effective in late-stage trials.
With this, the expectation of shots coming to India by the end of the year is high. According to Poonawala, the covalent vaccine has been shown to be effective during testing. Poonawalla said that during PM Modi’s visit to the Serum Institute, various issues such as vaccine preparation and pricing and logistics were discussed.
.
